Search Result
Results for "
BAY 59-7939-d4
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
37
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-147281
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research .
|
-
-
- HY-153045A
-
|
|
Deubiquitinase
|
Cancer
|
|
BAY-728 can be used as a negative control of BAY-805. BAY-805 is a potent and selective Inhibitor of USP21 .
|
-
-
- HY-150239
-
|
BAY-299N
|
DNA/RNA Synthesis
|
Cancer
|
|
BAY-364 (BAY-299N) is an inhibitor of the second bromine domain in TAF1. BAY-364 inhibits the TAF1 of Kasumi-1 cells, CD34 + cells and K562 cells with IC50 values of 1.0 µM, 10.4 µM and 10.0 µM respectively .
|
-
-
- HY-111515
-
|
|
Elastase
|
Inflammation/Immunology
|
|
BAY-678 racemate is a racemate of BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM. BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC).
|
-
-
- HY-160161
-
|
|
PPAR
|
Cancer
|
|
BAY-5094 is a PPAR gamma (PPARG) inverse agonist. BAY-5094 has oral activity. BAY-5094 can be used in the research of luminal bladder cancer .
|
-
-
- HY-153343
-
|
|
DGK
|
Cancer
|
|
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .
|
-
-
- HY-111457
-
|
|
Others
|
Inflammation/Immunology
|
|
BAY-677 is an inactive control for BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM . BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC) .
|
-
-
- HY-153343A
-
|
|
DGK
ERK
|
Cancer
|
|
(S)-BAY 2965501 is the left-handed isomer of BAY 2965501 (HY-153343). BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .
|
-
-
- HY-156965
-
|
|
Others
|
Metabolic Disease
Cancer
|
|
BAY-771, a structurally close pyrimidinedione, is a chemical probe with good lead-like properties and high permeability in Caco-2 cells (no hint of efflux). BAY-771 shows very weak inhibitory activity in the BCAT1 biochemical assay and no activity in BCAT2. BAY-771 can be used as a negative control of HY-148242 BAY-069. BAY-771 can be used for the research of tumor metabolism .
|
-
-
- HY-133083
-
|
|
c-Met/HGFR
|
Cancer
|
|
BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 acts as an epigenetics probe .
|
-
-
- HY-104001
-
|
|
Others
|
Cancer
|
|
BAY-524 is a potent Bub1 kinase inhibitor. BAY-524 inhibits the recombinant catalytic domain of human Bub1 with an IC50 of 450 nM. BAY-524 can be used for the research of anti-cancer in combination with other agents .
|
-
-
- HY-148242B
-
|
|
Others
|
Cancer
|
|
BAY-5000 (example 32) is a pyrimidinedione derivative. BAY-5000 can be used in the synthesis of cancer-related reagents .
|
-
-
- HY-162284
-
|
|
ADAMTS
|
Cardiovascular Disease
|
|
BAY-9835 is a potent and orally active ADAMTS7 and ADAMTS12 antagonist with IC50s of 6 nM and 30 nM, respectively. BAY-9835 is very selective against a range of off-targets and metalloproteases. BAY-9835 can be used for the atherogenesis research .
|
-
-
- HY-148242
-
BAY-069
1 Publications Verification
|
Others
|
Cancer
|
|
BAY-069 is a potent branched-chain amino acid transaminases 1 (BCAT1) and BCAT2 inhibitor with IC50 values of 31 nM and 153 nM, respectively. BAY-069 also can be used as a chemical probe. BAY-069 can be used tor research anticancer .
|
-
-
- HY-148242A
-
|
|
Others
|
Cancer
|
|
BAY-252 is a potent branched-chain amino acid transaminases 1 (BCAT1) and BCAT2 inhibitor with IC50s of 2 μM and 2 μM, respectively. BAY-069 also can be used as a chemical probe. BAY-069 can be used for the research of cancer .
|
-
-
- HY-112080
-
|
|
Histone Methyltransferase
|
Cancer
|
|
BAY-6035 is a potent, selective and substrate-competitive inhibitor of SMYD3. BAY-6035 inhibits methylation of MEKK2 peptide with an IC50 of 88 nM .
|
-
-
- HY-12421B
-
-
-
- HY-160188
-
|
|
PPAR
|
Cancer
|
|
BAY-9683 is an orally active covalent PPARG inverse agonist. BAY-9683 can be used in the study of diseases with overactive PPARG, such as luminal bladder cancer .
|
-
-
- HY-144863
-
|
|
GnRH Receptor
|
Cancer
|
|
BAY 1214784 is a potent, selective, and orally active antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R). BAY 1214784 is a spiroindoline derivative compound. BAY 1214784 effectively lowers plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability. BAY 1214784 has the potential for the research of uterine fibroids .
|
-
-
- HY-153369
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
Neurological Disease
|
|
BAY-747 is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
|
-
-
- HY-130605
-
|
|
P2X Receptor
|
Neurological Disease
|
|
BAY-1797 is a potent, orally active, and selective P2X4 antagonist, with an IC50 of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects .
|
-
-
- HY-148236
-
|
|
TRP Channel
|
Inflammation/Immunology
|
|
BAY-390 is a selective, across species active and brain penetrating TRPA1 inhibitor. BAY-390 inhibits hTRPA1 FLIPR, hTRPA1 Ephys, rTRPA1 FLIPR and rDRG Ephys with IC50s of 16, 82, 63 and 35 nM, respectively. BAY-390 can be used for the research of inflammation .
|
-
-
- HY-100017
-
|
|
GLUT
|
Cancer
|
|
BAY-876 is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4 . BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth .
|
-
-
- HY-160018
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models .
|
-
-
- HY-132293
-
|
|
DNA-PK
|
Cancer
|
|
BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC50=81 nM). BAY-8400 can be used for the research of cancer .
|
-
-
- HY-153045
-
|
|
Deubiquitinase
|
Cancer
|
|
BAY-805 is a selective inhibitor of ubiquitin-specific protease USP21. BAY-805 has high selectivity for deubiquitinating enzyme (DUB) targets, kinases, proteases and other common target enzymes .
|
-
-
- HY-148351
-
|
|
PPAR
|
Cancer
|
|
BAY-0069 is a potent and selective PPARγ inverse agonist with an IC50 value of 6.3 nM and 24 nM for human PPARγ and mouse PPARγ. BAY-0069 can be used to research cancer .
|
-
-
- HY-111457A
-
|
|
Elastase
|
Inflammation/Immunology
|
|
BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM. BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC).
|
-
-
- HY-112083
-
|
|
AMPK
|
Cancer
|
|
BAY-3827 is a potent and selective AMPK inhibitor with IC50 values of 1.4 nM at low (10 µM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines .
|
-
-
- HY-103019A
-
|
(±)-BAY-1251152; (±)-VIP152
|
CDK
|
Cancer
|
|
(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.
|
-
-
- HY-130248B
-
|
|
GnRH Receptor
|
Others
|
|
(R)-BAY-899 is the R-enantiomer of BAY-899. BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC50s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively .
|
-
-
- HY-130248
-
|
|
GnRH Receptor
|
Endocrinology
|
|
BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC50s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively. BAY-899 can reduce sex hormone levels .
|
-
-
- HY-160210
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
BAY-6096 is a potent, selective, and highly water-soluble adrenergic receptor α2B antagonist with an IC50 of 14 nM. BAY-6096 can effectively reduceα 2B receptor agonist-induced rat vascular contraction .
|
-
-
- HY-112645
-
-
-
- HY-19908B
-
|
|
Others
|
Metabolic Disease
|
|
(R)-BAY-85-8501 is the less active Enantiomer of BAY-85-8501. BAY-85-8501 is a selective and potent inhibitor of Human Neutrophil Elastase (HNE), with an IC50 of 65 pM .
|
-
-
- HY-10588
-
|
(±)-BAY K 8644
|
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
Bay K 8644 ((±)-Bay K 8644) is a racemate consisting of two isomers (R)-(+)-Bay-K-8644 and (S)-(-)-Bay-K-8644 . Bay K 8644 is a L-type Ca 2+ channel agonist with an EC50 of 17.3 nM. Bay K 8644 increases Ca 2+ influx through sarcolemmal Ca 2+ channels by increasing the open time of the channel. Bay K 8644 has vasoconstrictive effects .
|
-
-
- HY-W067427
-
|
|
IKK
|
Cancer
|
|
BAY32-5915 is a potent IKKα inhibitor with an IC50 value of 60 nM. BAY32-5915 has not affect Doxorubicin (HY-15142A)-induced NF-κB activation .
|
-
-
- HY-100020
-
-
-
- HY-100756
-
-
-
- HY-12871B
-
|
BAY-1143572
|
CDK
|
Cancer
|
|
Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC50 of 13 nM .
|
-
-
- HY-114398
-
BAY-293
1 Publications Verification
|
Ras
|
Cancer
|
|
BAY-293, a valuable chemical probe, blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM. BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS .
|
-
-
- HY-130249
-
|
|
GnRH Receptor
|
Endocrinology
|
|
BAY-298 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC50s of 96 nM, 23 nM and 78 nM for hLH (human LH) and rLH (rat LH) and cLH (cynomolgus monkey LH), respectively. BAY-298 can reduce sex hormone levels .
|
-
-
- HY-100029A
-
|
|
HBV
|
Infection
|
|
BAY 41-4109 racemate is the racemate of BAY 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
|
-
-
- HY-114398A
-
|
|
Others
|
Others
|
|
(S)-BAY-293 is a negative control of BAY 293. BAY 293 is a potent KRAS-SOS1 interaction inhibitor .
|
-
-
- HY-19546
-
-
-
- HY-139868
-
|
|
Others
|
Cancer
|
|
BAY-091 is a novel potent and highly selective inhibitor of the kinase PIP4K2A.
|
-
-
- HY-U00092B
-
|
|
Bacterial
|
Infection
|
|
(R,R)-BAY-Y 3118 is the R-enantiomer of BAY-Y 3118. (R,R)-BAY-Y 3118 shows weak bactericidal activity .
|
-
-
- HY-17513
-
|
BAY314666; BAY-MKH 3586
|
Others
|
Others
|
|
Amicarbazone(BAY-MKH3586; BAY314666) is a potent inhibitor of photosynthetic electron transport via binding to the Qb domain of photosystem II (PSII); herbicide with a broad spectrum of weed control.
|
-
-
- HY-P99718
-
|
BAY 1112623
|
ADC Antibody
|
Cancer
|
|
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 .
|
-
-
- HY-104000
-
|
|
Others
|
Cancer
|
|
BAY-320 is a Bub1 inhibitor, with an IC50 of 680 nM for human Bub1 in the presence of 2 mM ATP.
|
-
- HY-142658
-
|
|
Prostaglandin Receptor
|
Others
|
|
BAY-6672 is a potent and selective human Prostaglandin F (FP) receptor antagonist with an IC50 value of 11 nM.
|
-
- HY-148352
-
|
|
PPAR
|
Cancer
|
|
BAY-4931 is a potent, covalent and selective PPARγ inverse-agonist with an IC50 of 0.17 nM .
|
-
- HY-142658A
-
|
|
Prostaglandin Receptor
|
Others
|
|
BAY-6672 hydrochloride is a potent and selective human Prostaglandin F (FP) receptor antagonist with an IC50 value of 11 nM.
|
-
- HY-121086
-
-
- HY-111539
-
|
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
|
BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC50 of 15.3 nM for human EP4-R. BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for endometriosis research .
|
-
- HY-112081
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
BAY-707 is a substrate-competitive, highly potent and selective inhibitor of MTH1(NUDT1) with an IC50 of 2.3 nM. BAY-707 has a good pharmacokinetic (PK) profile to other MTH1 compounds and is well-tolerated in mice, but shows a clear lack of in vitro or in vivo anticancer efficacy .
|
-
- HY-135829
-
|
|
Aryl Hydrocarbon Receptor
|
Cancer
|
|
BAY 2416964 is a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 192, has an IC50 of 341 nM. BAY 2416964 has the potential for solid tumors treatment .
|
-
- HY-10257
-
|
BAY 11-7083
|
NF-κB
Ferroptosis
Apoptosis
|
Cancer
|
|
BAY 11-7085 (BAY 11-7083) is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC50 of 10 μM .
|
-
- HY-103020
-
|
|
Others
|
Cancer
|
|
BAY-1816032 is a potent and oral available BUB1 (budding uninhibited by benzimidazoles 1) kinase inhibitor with an IC50 of 7 nM.
|
-
- HY-152106
-
-
- HY-14992
-
-
- HY-101566
-
|
BAY 1895344
|
ATM/ATR
|
Cancer
|
|
Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib has anti-tumor activity . Elimusertib can be used for the research of solid tumors and lymphomas .
|
-
- HY-145707
-
-
- HY-112082
-
|
|
ERK
|
Cancer
|
|
BAY885 is a highly potent and selective ERK5 inhibitor with an IC50 of 35 nM. BAY885 shows weak inhibition on others kinases .
|
-
- HY-119254
-
-
- HY-160160
-
|
|
PPAR
|
Cancer
|
|
BAY-5516 is a inverse-agonist o PPARG, with the IC50 value of 6.1±3.6 nM that has anti-tumor effect .
|
-
- HY-104028B
-
|
|
Others
|
Neurological Disease
|
|
(S)-BAY 73-6691 is the isomer of BAY 73-6691 (HY-104028), and can be used as an experimental control. BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitor .
|
-
- HY-145924
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
BAY 2666605 is an orally active PDE3A and PDE3B inhibitor with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 is a PDE3A-SLFN12 complex inducer (WO2019025562A1; example 135) .
|
-
- HY-142661
-
-
- HY-100886
-
|
|
|
|
|
BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth .
|
-
- HY-111767
-
|
|
Adenosine Receptor
|
Inflammation/Immunology
|
|
BAY-545 is a potent and selective A2B adenosine receptor antagonist, with an IC50 of 59 nM. BAY-545 also exhibits IC50s of 66, 400, 280 nM for human, mouse, rat A2B adenosine receptor in cells, respectively, and a Ki of 97 nM for human A2B adenosine receptor, with more selectivity over A1, A2A, and A3 adenosine receptor .
|
-
- HY-139572
-
|
BAY-2327949
|
Vasopressin Receptor
|
Metabolic Disease
|
|
Enuvaptan (BAY-2327949) is a vasopressin receptor antagonist and has the potential for research into renal and cardiovascular diseases .
|
-
- HY-145351
-
-
- HY-107609
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
BAY-u 9773 is a non-selective antagonist of the CysLT receptors (cysteinyl leukotrienes receptors) with about the same IC50 for CysLT 1 and CysLT 2. BAY-u9773 is used for the inhibition of LT responses .
|
-
- HY-104028
-
-
- HY-19908
-
|
|
Elastase
|
Metabolic Disease
|
|
BAY-85-8501 is a selective, reversible and potent inhibitor of Human Neutrophil Elastase (HNE), with an IC50 of 65 pM.
|
-
- HY-U00092
-
|
|
Bacterial
|
Infection
|
|
BAY-Y 3118 is a new chlorofluoroquinolone with antimicrobial activity.
|
-
- HY-12858
-
|
BAY 1161909
|
Mps1
|
Cancer
|
|
Empesertib (BAY 1161909) is a potent Mps1 inhibitor, with an IC50 of < 1 nM.
|
-
- HY-113926
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect .
|
-
- HY-133080
-
|
|
GnRH Receptor
|
Cancer
|
|
BAY-784 is a gonadotropin releasing hormone receptor (GnRH-R) antagonist probe with IC50s of 21 and 24 nM for human and rat GnRH-R, respectively .
|
-
- HY-78237
-
-
- HY-103019B
-
|
(R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152
|
CDK
|
Cancer
|
|
(-)-Enitociclib ((R)-Enitociclib) is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.
|
-
- HY-13453
-
BAY 11-7082
Maximum Cited Publications
271 Publications Verification
BAY 11-7821
|
IKK
Deubiquitinase
Autophagy
Apoptosis
NF-κB
|
Inflammation/Immunology
Cancer
|
|
BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells .
|
-
- HY-50949A
-
|
|
IKK
|
Inflammation/Immunology
|
|
Bay 65-1942 R form is the less active R-form of Bay 65-1942. Bay 65-1942 is an ATP-competitive and selective IKKβ inhibitor.
|
-
- HY-111449
-
|
AHR antagonist 1
|
Aryl Hydrocarbon Receptor
|
Inflammation/Immunology
Cancer
|
|
BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an IC50 of 39.9 nM in in U87 glioblastoma cells. BAY-218 can be used for the research of cancer or conditions with dysregulated immune responses .
|
-
- HY-107424
-
BAY-299
2 Publications Verification
|
Epigenetic Reader Domain
|
Cancer
|
|
BAY-299 is a very potent, dual inhibitor with IC50s of 67 nM for BRPF2 bromodomains (BD), 8 nM for TAF1 BD2, and 106 nM for TAF1L BD2.
|
-
- HY-107513
-
|
|
mGluR
|
Neurological Disease
Cancer
|
|
BAY 36-7620 is a potent and noncompetitive antagonist of mGlu1 Receptor (IC50=0.16 μM) with inverse agonist activity. BAY 36-7620 inhibits tumor growth and prolongs the survival of mice with tumors by inhibiting mGlu1 receptor. BAY 36-7620 suppresses AKT phosphorylation in A549 tumors. BAY 36-762 has neuroprotective effect in acute subdural hematoma rat model.BAY 36-7620 is used in non-small cell lung cancer and breast cancer research .
|
-
- HY-W062836
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research .
|
-
- HY-76474
-
|
|
Syk
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
|
-
- HY-14985
-
|
|
Syk
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM . BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
|
-
- HY-12421
-
-
- HY-P1160
-
|
|
GCGR
|
Metabolic Disease
|
|
Bay 55-9837 is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes .
|
-
- HY-145940
-
|
BRD3727
|
Others
|
Cancer
|
|
BAY-204 is an inhibitor of Casein kinase 1 alpha and delta (CSNK1α and δ) useful for the research of proliferative disorders.
|
-
- HY-148232
-
|
|
CCR
|
Inflammation/Immunology
|
|
BAY-3153 is a selective CCR1 (C-C motif chemokine receptor 1) antagonist (human IC50=3 nM; rat IC50=11 nM; mice IC50=81 nM) .
|
-
- HY-145939
-
|
BRD5846
|
Others
|
Cancer
|
|
BAY-888 exhibits IC50 value of 1.5 nM and 5.5 nM towards CSNK1A1 and CSNK1D, respectively.
|
-
- HY-B0175
-
-
- HY-156967
-
|
|
MDM-2/p53
|
Cancer
|
|
BAY 1892005 is a regulator of p53 protein and acts on p53 condensates without causing mutant p53 reactivation .
|
-
- HY-112316A
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome .
|
-
- HY-120944
-
|
|
MMP
|
Inflammation/Immunology
|
|
BAY-7598 is a potent, orally bioavailable, and selective MMP12 inhibitor probe with IC50s of 0.085, 0.67 and 1.1 nM for human MMP12, murine MMP12, and rat MMP12, respectively .
|
-
- HY-100029B
-
|
|
HBV
|
Infection
|
|
Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
|
-
- HY-133117
-
|
|
IKK
|
Cancer
|
|
BAY-985 is a highly potent, orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy .
|
-
- HY-16985
-
|
ODM-201; BAY-1841788
|
Androgen Receptor
|
Cancer
|
|
Darolutamide (ODM-201;BAY-1841788) is a potent androgen receptor (AR) antagonist with an IC50 of 26 nM in in vitro assay.
|
-
- HY-122312
-
|
|
Monocarboxylate Transporter
|
Cancer
|
|
BAY-8002 is a potent, selective, orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4. Anti-tumor activity .
|
-
- HY-103171
-
|
|
Adenosine Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50 = 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model .
|
-
- HY-15125
-
-
- HY-144003
-
-
- HY-12871
-
|
BAY-1143572 Racemate
|
CDK
|
Cancer
|
|
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
|
-
- HY-P1160A
-
|
|
GCGR
|
Metabolic Disease
|
|
Bay 55-9837 TFA is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes .
|
-
- HY-15124
-
-
- HY-50948
-
-
- HY-118941
-
|
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure .
|
-
- HY-12871C
-
|
BAY-1143572 S-Enantiomer
|
CDK
|
Cancer
|
|
Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective CDK9 inhibitor, which inhibits CDK9/CycT1 with an IC50 of 16 nM.
|
-
- HY-16774
-
-
- HY-100488
-
|
|
Cannabinoid Receptor
|
Cancer
|
|
Bay 59-3074 is a selective cannabinoid CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors, respectively. Bay 59-3074 has analgesic properties .
|
-
- HY-109170
-
|
BAY 1817080
|
P2X Receptor
|
Inflammation/Immunology
|
|
Eliapixant (BAY 1817080) is a potent and selective antagonist of P2X3 receptor, with an IC50 of 8 nM. Eliapixant can be used for the research of refractory chronic cough .
|
-
- HY-12376
-
|
|
Guanylate Cyclase
|
Inflammation/Immunology
|
|
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research .
|
-
- HY-B1151
-
|
BAY-e 6975
|
Fungal
|
Infection
|
|
Climbazole (BAY-e 6975) is a potent antifungal agent. Climbazole also is a potent inducer of rat hepatic cytochrome P450 .
|
-
- HY-110242
-
|
|
Mps1
Apoptosis
|
Cancer
|
|
Mps-BAY2a is a monopolar spindle 1 (MPS1) inhibitor with an IC50 of 1 nM against human MPS1. Mps-BAY2a induces mitotic aberrations and apoptosis in cancer cells .
|
-
- HY-B0301
-
-
- HY-100029
-
|
|
HBV
|
Infection
|
|
BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
|
-
- HY-113715
-
|
BAY 9015; Menichlopholan; Menichlofolan; Bilevon
|
Parasite
|
Infection
|
|
Niclofolan (BAY 9015) is an orally active anthelmintic agent. Niclofolan can be used in the research of parasite infection .
|
-
- HY-12859
-
|
|
Mps1
|
Cancer
|
|
BAY 1217389 is a potent, and selective inhibitor of the monopolar spindle 1 (MPS1) kinase with an IC50 value less than 10 nM.
|
-
- HY-P99465
-
|
BAY 1093884
|
Thrombin
|
Cardiovascular Disease
|
|
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
|
-
- HY-119744
-
|
|
Cannabinoid Receptor
|
Neurological Disease
|
|
BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist, with Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties .
|
-
- HY-104028A
-
-
- HY-134877
-
|
|
EGFR
|
Cancer
|
|
BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG) .
|
-
- HY-B0356
-
-
- HY-B0356B
-
|
BAY-09867 hydrochloride monohydrate
|
Topoisomerase
Apoptosis
Antibiotic
Bacterial
Mitochondrial Metabolism
Reactive Oxygen Species
|
Infection
Cancer
|
|
Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
|
-
- HY-17402
-
-
- HY-B0265
-
-
- HY-101566A
-
|
BAY 1895344 hydrochloride
|
ATM/ATR
|
Cancer
|
|
Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib hydrochloride has anti-tumor activity . Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas .
|
-
- HY-102056
-
|
|
Others
|
Metabolic Disease
|
|
BAY 59-9435 is a potent and selective inhibitor of Hormone Sensitive Lipase (HSL), with an IC50 of 0.023 μM.
|
-
- HY-15836
-
-
- HY-B0284
-
-
- HY-112316B
-
-
- HY-B0356S1
-
|
BAY-09867-d8
|
Bacterial
Antibiotic
|
Infection
|
|
Ciprofloxacin-d8 is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
- HY-P99007
-
|
BAY 1179470
|
FGFR
|
Cancer
|
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
|
-
- HY-115494
-
|
Neladenoson bialanate hydrochloride; BAY-1067197 hydrochloride
|
Adenosine Receptor
|
Cardiovascular Disease
|
|
Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) hydrochloride is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate hydrochloride has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases .
|
-
- HY-123353
-
|
Neladenoson bialanate; BAY-1067197
|
Adenosine Receptor
|
Cardiovascular Disease
|
|
Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases .
|
-
- HY-50949
-
-
- HY-103019
-
|
(+)-Enitociclib; (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
|
CDK
|
Cancer
|
|
Enitociclib ((+)-Enitociclib) is an enanthiomer of BAY-1251152 with rotation (+). Enitociclib is a potent and selective CDK9 inhibitor with an IC50 of 3 nM. Enitociclib has anti-tumour activity .
|
-
- HY-111939
-
|
BAY-NTN 6867
|
Microtubule/Tubulin
|
Others
|
|
Amiprofos methyl (BAY-NTN 6867) is a phosphoric amide herbicide. Amiprofos methyl is a specific and potent antimicrotubule agent. Amiprofos methyl directly poisons microtubule dynamics in plant cells .
|
-
- HY-19546A
-
-
- HY-B0356S
-
|
BAY-09867-d8 (hydrochloride)
|
Bacterial
Antibiotic
|
Infection
|
|
Ciprofloxacin-d8 (hydrochloride) is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
- HY-14691
-
|
BAY 869766; RDEA119
|
MEK
|
Cancer
|
|
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.
|
-
- HY-P99794
-
|
BAY 1213790
|
Factor Xa
|
Cardiovascular Disease
|
|
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
|
-
- HY-B1843
-
|
BAY 33172; Furidazole
|
Fungal
|
Infection
|
|
Fuberidazole (BAY 33172; Furidazole) is a fungicide. Fuberidazole shows a synergistic effect with cucurbituril (CB) macromolecules, such as CB7 and CB8. Studies have shown that, CB8 induces pKa shifts on Fuberidazole. Fuberidazole significantly inhibits the growth of B. cinerea .
|
-
- HY-16774S
-
|
BAY1021189-d3 hydrochloride
|
Isotope-Labeled Compounds
|
Others
|
|
Vericiguat-d3 (BAY1021189-d3) hydrochloride is a deuterated Vericiguat with tracer functionality. Vericiguat is an orally available stimulator of guanylate cyclase .
|
-
- HY-B1466
-
|
BAY-f 1353 sodium
|
Bacterial
Antibiotic
|
Infection
|
|
Mezlocillin (BAY-f 1353) sodium is a β-lactam antibiotic, a semisynthetic and extended-spectrum antibiotic. Mezlocillin sodium is active against both gram-negative and gram-positive bacteria. Mezlocillin sodium can be used in bacterial infection research .
|
-
- HY-B1466A
-
|
BAY-f 1353
|
|
|
|
Mezlocillin (BAY-f 1353) is a β-lactam antibiotic, a semisynthetic and extended-spectrum antibiotic. Mezlocillin is active against both gram-negative and gram-positive bacteria. Mezlocillin can be used in bacterial infection research .
|
-
- HY-133117A
-
|
|
IKK
|
Cancer
|
|
(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective TBK1 inhibitor with an IC50 of 1.5 nM. Antitumor efficacy .
|
-
- HY-106616
-
|
BAY-g 2821; Edrul
|
Others
|
Cardiovascular Disease
|
|
Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive effects. Muzolimine can be used for the research of cardiovascular disease .
|
-
- HY-100018
-
|
|
Akt
|
Cancer
|
|
BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.
|
-
- HY-16194
-
|
BAY o 1248
|
Others
|
Metabolic Disease
|
|
Emiglitate (BAY o 1248) is a potent, selective and competitive inhibitor of α-glucoside hydrolase.
|
-
- HY-B0356A
-
|
BAY-09867 monohydrochloride
|
Topoisomerase
Apoptosis
Antibiotic
Bacterial
Mitochondrial Metabolism
Reactive Oxygen Species
|
Infection
Cancer
|
|
Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
|
-
- HY-W040298
-
|
BAY-09867 lactate
|
Topoisomerase
Apoptosis
Antibiotic
Bacterial
Mitochondrial Metabolism
Reactive Oxygen Species
|
Infection
Cancer
|
|
Ciprofloxacin (Bay-09867) lactate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin lactate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin lactate has anti-proliferative activity and induces apoptosis. Ciprofloxacin lactate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
|
-
- HY-W353258
-
|
BAY 12-8039 monohydrate
|
Bacterial
Antibiotic
|
Infection
|
|
Moxifloxacin (BAY 12-8039) hydrochloride monohydrate is an orally active bacterial inhibitor that is effective against Streptococcus pneumoniae. Moxifloxacin hydrochloride monohydrate can be used in tuberculosis research .
|
-
- HY-101566S
-
|
BAY 1895344-d3
|
ATM/ATR
|
Cancer
|
|
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .
|
-
- HY-B0089A
-
|
BAY-g 5421 sulfate
|
Glucosidase
|
Metabolic Disease
|
|
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-112316
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC50 <100 nM).
|
-
- HY-66011
-
|
BAY 12-8039
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia .
|
-
- HY-139374
-
|
BAY 1834845
|
IRAK
|
Inflammation/Immunology
|
|
Zabedosertib (BAY 1834845) is a selective, orally active IRAK4 inhibitor with immunomodulatory potential, IC50 is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors . Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation .
|
-
- HY-106484
-
|
BAY-P 4495
|
5-HT Receptor
|
Neurological Disease
|
|
Tiflucarbine (BAY-P 4495) is a tetrahydrothieno-7-carboline derivative. Tiflucarbine is a potent antidepressant agent that binds at central serotonin (5-HT) binding sites. Tiflucarbine is a nonselective 5-HT (5-HT1 and 5-HT2) agonist .
|
-
- HY-137431
-
|
BAY-2433334
|
Factor Xa
|
Cardiovascular Disease
|
|
Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM .
|
-
- HY-50903
-
|
BAY 59-7939
|
Factor Xa
|
Cardiovascular Disease
Cancer
|
|
Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM) .
|
-
- HY-B0424
-
|
BAY-E-5009
|
Calcium Channel
Autophagy
|
Cardiovascular Disease
|
|
Nitrendipine (BAY-E-5009), an analogue of Nifedipine (HY-B0284), is a dihydropyridine calcium channel blocker with vasodilator action. Nitrendipine has antihypertensive effect .
|
-
- HY-10527
-
|
BAY 57-9352
|
c-Kit
PDGFR
VEGFR
|
Cancer
|
|
Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively.
|
-
- HY-12654
-
|
BAY 85-3934
|
HIF/HIF Prolyl-Hydroxylase
|
Cardiovascular Disease
|
|
Molidustat (BAY 85-3934) is a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with mean IC50 values of 480 nM for PHD1, 280 nM for PHD2, and 450 nM for PHD3.
|
-
- HY-10527C
-
|
BAY 57-9352 mesylate
|
VEGFR
PDGFR
c-Kit
|
Cancer
|
|
Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively .
|
-
- HY-B0502
-
-
- HY-B0497S1
-
|
BAY2353-13C6
|
Isotope-Labeled Compounds
STAT
Parasite
Antibiotic
|
Infection
Cancer
|
|
Niclosamide- 13C6 is the 13C6 labeled Niclosamide. Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits STAT3 with IC50 of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.
|
-
- HY-P99802
-
|
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-12168B
-
|
(Rac)-BAY 12-9566
|
MMP
|
Cancer
|
|
(Rac)-Tanomastat ((Rac)-BAY 12-9566) is the racemate of Tanomastat. Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .
|
-
- HY-137431A
-
|
(R)-BAY-2433334
|
Others
|
Cardiovascular Disease
|
|
(R)-Asundexian ((R)-BAY-2433334) is the enantiomer of Asundexian (HY-137431). (R)-Asundexian can be used in studies of cardiovascular disease (especially thrombotic or thromboembolic disease), edema, and ophthalmic disease .
|
-
- HY-B0284R
-
|
BAY-a-1040 (Standard)
|
Calcium Channel
Autophagy
|
Cardiovascular Disease
Cancer
|
|
Nifedipine (Standard) is the analytical standard of Nifedipine. This product is intended for research and analytical applications. Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
|
-
- HY-B0497
-
|
BAY2353
|
STAT
Parasite
Antibiotic
|
Infection
Cancer
|
|
Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .
|
-
- HY-B0497B
-
|
BAY2353 monohydrate
|
STAT
Antibiotic
Parasite
|
Infection
Cancer
|
|
Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used in parasitic infection research . Niclosamide monohydrate is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells . Niclosamide monohydrate has biological activities against cancer, and inhibits DNA replication in Vero E6 cells .
|
-
- HY-B0497A
-
|
BAY2353 sodium
|
Antibiotic
STAT
Parasite
|
Infection
Cancer
|
|
Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research . Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells . Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells .
|
-
- HY-111985
-
|
BAY Vq 7813
|
5-HT Receptor
Adenylate Cyclase
|
Others
|
|
Revospirone (BAY Vq 7813) is a partial agonist of the 5-HT1A receptor with a Ki of 2 nmol/L. Revospirone inhibits adenylate cyclase activity with an IC50 of 124 nmol/L .
|
-
- HY-13308
-
|
BAY 73-4506 hydrochloride
|
VEGFR
Autophagy
PDGFR
Raf
RET
|
Cancer
|
|
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .
|
-
- HY-19672
-
|
BAY 19-8004
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties .
|
-
- HY-B0089
-
|
BAY g 5421
|
Glucosidase
|
Metabolic Disease
|
|
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-100019
-
|
BAY1163877
|
FGFR
|
Cancer
|
|
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/FLT4), 201 nM (FGFR4), respectively .
|
-
- HY-10319
-
BAY-549
2 Publications Verification
ROCK-IN-2; Azaindole 1; TC-S 7001
|
ROCK
|
Cardiovascular Disease
|
|
BAY-549 (Azaindole 1) is an orally active and ATP-competitive ROCK inhibitor with IC50s of 0.6 and 1.1 nM for human ROCK-1 and ROCK-2, respectively .
|
-
- HY-B0509A
-
|
BAY 41-6551
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies .
|
-
- HY-B0175S
-
|
BAY-i 9142-d3
|
Isotope-Labeled Compounds
|
Infection
|
|
Toltrazuril-d3 is deuterated labeled Toltrazuril. Toltrazuril (BAY-i 9142) is an antiprotozoal agent that acts upon Coccidia parasites.
|
-
- HY-B0284S1
-
-
- HY-66011R
-
|
BAY 12-8039 (Standard)
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Moxifloxacin (Hydrochloride) (Standard) is the analytical standard of Moxifloxacin (Hydrochloride). This product is intended for research and analytical applications. Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia .
|
-
- HY-10331
-
|
BAY 73-4506
|
VEGFR
Autophagy
PDGFR
Raf
RET
c-Kit
FGFR
Tie
|
Cancer
|
|
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
|
-
- HY-10331A
-
|
BAY 73-4506 monohydrate
|
VEGFR
Autophagy
PDGFR
Raf
RET
FGFR
c-Kit
Tie
|
Cancer
|
|
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
|
-
- HY-B0509
-
|
BAY 41-6551 hydrate
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Amikacin hydrate (BAY 41-6551 hydrate) is an aminoglycoside antibiotic and a semisynthetic analog of kanamycin. Amikacin hydrate is bactericidal, acting directly on the 30S and 50S bacerial ribosomal subunits to inhibit protein synthesis. Amikacin hydrate is very active against most Gram-negative bacteria including gentamicin- and tobramycin-resistant strains. Amikacin hydrate also inhibits the infections caused by susceptible Nocardia and nontuberculous mycobacteria .
|
-
- HY-10331B
-
|
BAY 73-4506 mesylate
|
VEGFR
PDGFR
RET
Raf
c-Kit
FGFR
Autophagy
Tie
|
Cancer
|
|
Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .
|
-
- HY-14165
-
-
- HY-12168
-
|
BAY 12-9566
|
MMP
|
Cancer
|
|
Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .
|
-
- HY-111372
-
|
BAY 94-8862
|
Mineralocorticoid Receptor
|
Cardiovascular Disease
|
|
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
|
-
- HY-B0497C
-
|
BAY2353 olamine
|
STAT
Parasite
Antibiotic
|
Infection
Cancer
|
|
Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research . Niclosamide olamin is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells . Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells .
|
-
- HY-111372A
-
|
(Rac)-BAY 94-8862
|
Mineralocorticoid Receptor
|
Cardiovascular Disease
|
|
(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold) .
|
-
- HY-B1151S
-
|
BAY-e 6975-d4
|
Fungal
|
Infection
|
|
Climbazole-d4 is the deuterium labeled Climbazole. Climbazole (BAY-e 6975) is a potent antifungal agent. Climbazole also is a potent inducer of rat hepatic cytochrome P450[2].
|
-
- HY-10201A
-
|
BAY 43-9006 Tosylate
|
Raf
VEGFR
FLT3
Autophagy
Ferroptosis
Apoptosis
|
Cancer
|
|
Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator .
|
-
- HY-10201
-
|
BAY 43-9006
|
Raf
VEGFR
FLT3
Autophagy
Apoptosis
Ferroptosis
|
Cancer
|
|
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .
|
-
- HY-B0502A
-
|
BAY Vp 2674 monohydrochloride; PD160788 monohydrochloride
|
Bacterial
Antibiotic
Endogenous Metabolite
Orthopoxvirus
|
Infection
|
|
Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis. Enrofloxacin monohydrochloride shows inhibitory activity against vaccinia virus (VV).
|
-
- HY-17402S
-
-
- HY-66011B
-
|
(Rac)-BAY 12-8039 free base
|
Bacterial
Antibiotic
|
Infection
|
|
(Rac)-Moxifloxacin ((Rac)-BAY 12-8039 free base) is the isoform of Moxifloxacin Hydrochloride (HY-66011), which is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia .
|
-
- HY-15303B
-
|
AIC316 mesylate hydrate; BAY 57-1293 mesylate hydrate
|
HSV
|
Infection
|
|
Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
|
-
- HY-15303A
-
|
AIC316 mesylate; BAY 57-1293 mesylate
|
HSV
|
Infection
|
|
Pritelivir mesylate (BAY 57-1293 mesylate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
|
-
- HY-12959A
-
|
BAY x 3702
|
|
|
|
Repinotan hydrochloride (BAY x 3702) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with Ki values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus Repinotan hydrochloride has a weak affinity for other related receptors. Repinotan hydrochloride has pronounced neuroprotective effects .
|
-
- HY-17402S3
-
-
- HY-15346
-
|
BAY 80-6946
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
|
-
- HY-15346A
-
|
BAY 80-6946 dihydrochloride
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .
|
-
- HY-B0509B
-
|
BAY 41-6551 disulfate
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Amikacin disulfate (BAY 41-6551 dissulfate) is an aminoglycoside antibiotic and a semisynthetic analog of kanamycin. Amikacin disulfate is bactericidal, acting directly on the 30S and 50S bacerial ribosomal subunits to inhibit protein synthesis. Amikacin disulfate is very active against most Gram-negative bacteria including gentamicin- and tobramycin-resistant strains. Amikacin disulfate also inhibits the infections caused by susceptible Nocardia and nontuberculous mycobacteria .
|
-
- HY-107813
-
|
BAY 41-6551 sulfate
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Amikacin sulfate (BAY 41-6551 sulfate) is an aminoglycoside antibiotic and a semisynthetic analog of kanamycin. Amikacin sulfate is bactericidal, acting directly on the 30S and 50S bacerial ribosomal subunits to inhibit protein synthesis. Amikacin sulfate is very active against most Gram-negative bacteria including gentamicin- and tobramycin-resistant strains. Amikacin sulfate also inhibits the infections caused by susceptible Nocardia and nontuberculous mycobacteria .
|
-
- HY-B0497G
-
|
BAY2353
|
Antibiotic
Parasite
STAT
|
Cancer
|
|
Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .
|
-
- HY-B0502S
-
-
- HY-12959
-
|
BAY x 3702 free base
|
5-HT Receptor
|
Neurological Disease
|
|
Repinotan (BAY x 3702 free base) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with Ki values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus). Repinotan has a weak affinity for other related receptors. Repinotan has pronounced neuroprotective effects .
|
-
- HY-B0502AS
-
-
- HY-B0502AS1
-
|
BAY Vp 2674-d5 (hydriodide); PD160788-d5 (hydriodide)
|
Bacterial
Antibiotic
Endogenous Metabolite
|
Infection
|
|
Enrofloxacin-d5 (hydriodide) is the deuterium labeled Enrofloxacin (monohydrochloride). Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.
|
-
- HY-66011S
-
|
rac cis-BAY 12-8039-d4
|
Isotope-Labeled Compounds
Bacterial
Antibiotic
|
Infection
|
|
rac cis-Moxifloxacin-d4 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
|
-
- HY-66011AS3
-
|
BAY 12-8039-d3-1
|
Isotope-Labeled Compounds
|
Infection
|
|
Moxifloxacin-d3-1 hydrochloride (BAY 12-8039-d3-1) is a deuterium labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia .
|
-
- HY-14165A
-
|
(S)-BAY X 1005; (S)-DG-031
|
Leukotriene Receptor
FLAP
|
Inflammation/Immunology
|
|
(S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood .
|
-
- HY-B0497BS
-
|
BAY2353-13C6 monohydrate
|
STAT
Parasite
Antibiotic
|
|
|
Niclosamide- 13C6 (monohydrate) is the 13C labeled Niclosamide monohydrate[1]. Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used in parasitic infection research[2]. Niclosamide monohydrate is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[5]. Niclosamide monohydrate has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[3][4][6].
|
-
- HY-66011AS4
-
|
BAY 12-8039-13C,d3
|
Isotope-Labeled Compounds
|
Cancer
|
|
Moxifloxacin- 13C,d3 hydrochloride (BAY 12-8039- 13C,d3) is 13C and deuterated labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
|
-
- HY-10331S1
-
|
BAY 73-4506-13C,d3
|
VEGFR
Autophagy
PDGFR
Raf
RET
|
Cancer
|
|
Regorafenib- 13C,d3 is the 13C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
|
-
- HY-120422S
-
-
- HY-N0345
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Liriope muscari baily saponins C is one of major active compounds of L. muscari (Decne.) Baily. Liriope muscari baily saponins C possesses strong anti-inflammatory, immunopharmacological and cardioprotective activities. Liriope muscari baily saponins C has been studied as a candidate agent for cancer metastasis .
|
-
![(3β,25S)-Spirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-xylopyranosyl-(1→3)]-β-D-glucopyranoside](//file.medchemexpress.com/product_pic/hy-n0345.gif)
- HY-14779
-
-
- HY-13914
-
|
BAY 1000394
|
CDK
|
Cancer
|
|
Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.
|
-
- HY-109136
-
|
BAY 1101042
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
Runcaciguat is an orally active stimulator of soluble guanylate cyclase, and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists .
|
-
- HY-109173
-
|
BAY 1902607
|
P2X Receptor
|
Neurological Disease
|
|
Filapixant is a purinoreceptor antagonist extracted from patent WO2016091776A1, example 348. Filapixant is the active reference substance of Eliapixant .
|
-
- HY-137446
-
-
- HY-109133
-
|
BAY 1753011
|
Vasopressin Receptor
|
Neurological Disease
Metabolic Disease
|
|
Pecavaptan is an orally active and dual antagonist of V1a/V2 receptor (Ki=0.5 nM and 0.6 nM for human, respectively). Pecavaptan promotes an increase in urine production, which reduces the associated symptoms of water retention and edema .
|
-
- HY-16775
-
|
BAY 1002670
|
Progesterone Receptor
|
Cancer
|
|
Vilaprisan is a selective progesterone receptor modulator (SPRM), which targets progesterone receptors. Vilaprisan can inhibit cell proliferation and stimulate apoptosis. Vilaprisan has oral efficacy and anti-proliferative activity against uterine leiomyoma (UF ).
|
-
- HY-B0481
-
|
BAY1099; BAY-m1099
|
Others
|
Metabolic Disease
|
|
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose.
|
-
- HY-17513R
-
|
BAY314666 (Standard); BAY-MKH 3586 (Standard)
|
Others
|
Others
|
|
Amicarbazone (Standard) is the analytical standard of Amicarbazone. This product is intended for research and analytical applications.
|
-
- HY-19337
-
|
BAY 1896953; ORM-15341
|
Androgen Receptor
|
Endocrinology
|
|
Ketodarolutamide (ORM-15341) is a potent and full antagonist for human AR (hAR) with IC50 values of 38 nM as shown by transactivation assays in AR-HEK293 cells stably expressing full-length hAR and an androgen-responsive luciferase reporter gene construct.
|
-
- HY-150735
-
|
|
IRAK
|
Inflammation/Immunology
|
|
IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .
|
-
- HY-109059
-
|
BAY1142524
|
Others
|
Cardiovascular Disease
|
|
Fulacimstat is an orally available chymase inhibitor, with IC50s of 4, 3 nM for human and hamster chymase enzyme, respectively.
|
-
- HY-109077
-
-
- HY-10216
-
|
BAY 869766 R enantiomer; RDEA119 R enantiomer
|
MEK
|
Cancer
|
|
Refametinib R enantiomer is a MEK inhibitor extracted from patent WO2007014011A2, compound 1022, has an EC50 of 2.0-15 nM.
|
-
- HY-119892
-
|
NSC 320846; BAY-H 2049
|
Topoisomerase
|
Cancer
|
|
Batracylin (NSC320846) is a potent DNA Topoisomerases I and DNA Topoisomerases II inhibitor. Batracylin shows cytotoxicity and antiproliferative activity. Batracylin induces DNA breaks .
|
-
- HY-17402S1
-
-
- HY-17402S2
-
-
- HY-14181
-
-
- HY-14917
-
-
- HY-B0745
-
-
- HY-14181A
-
-
- HY-101476
-
|
BAY 44-4400
|
Parasite
|
Infection
|
|
Emodepside (PF 1022-221) is a cyclooctadepsipeptide with broad-spectrum anthelmintic activity.
|
-
- HY-108261
-
|
BAY 38-4766
|
CMV
|
Infection
|
|
Tomeglovir is a potent anti-CMV agent, inhibiting processing of viral DNA-concatemers, with IC50s of 0.34 μM and 0.039 μM for HCMV and MCMV.
|
-
- HY-119847
-
|
BAY-W-6341
|
Fungal
|
Infection
|
|
Abafungin, a antifungal agent, inhibitis the transmethylation at the C-24 position of the sterol side chain, catalyzed by the enzyme sterol-C-24-methyltransferase.
|
-
- HY-100121
-
-
- HY-19502
-
|
Artemifone; BAY 44-9585
|
Parasite
CMV
|
Infection
|
|
Artemisone (Artemifone) is a potent and semi-synthetic antimalarial, inhibits P. falciparum strains, with a mean IC50 of 0.83 nM . Artemisone is also a potent inhibitor of human CMV .
|
-
- HY-109171
-
-
- HY-135356
-
|
|
Drug Metabolite
|
Cardiovascular Disease
|
|
m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and agent of choice for cardiac insufficiencies .
|
-
- HY-B0481S1
-
-
- HY-15303
-
|
AIC316; BAY 57-1293
|
HSV
|
Infection
|
|
Pritelivir (AIC316), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
|
-
- HY-66011A
-
|
BAY 12-8039 free base
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia .
|
-
- HY-W748456
-
|
|
Others
|
Others
|
|
Apigenin-7-O-sulfate is a major flavonoid which is found to be a distinctive feature of plants from the Bay of Cadiz and can be extracted from these plants .
|
-
- HY-139788A
-
|
ION-957943; BAY-2976217; IONIS-FXI-LRx sodium
|
Others
|
Cardiovascular Disease
|
|
Fesomersen (sodium) is an antisense oligonucleotide designed to inhibit the production of Factor XI.
|
-
- HY-106997
-
|
BAY 10-8888; PLD 118
|
Fungal
|
Infection
|
|
Icofungipen is an orally active antifungal agent. Icofungipen is the representative of beta amino acids, is toxic against Candida species. Icofungipen protects infected mice survival from C. albicans infection .
|
-
- HY-B0265S
-
|
|
Autophagy
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
Nimodipine-d7 is the deuterium labeled Nimodipine. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].
|
-
- HY-76948
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
|
-
- HY-135356R
-
|
|
Drug Metabolite
|
Cardiovascular Disease
|
|
m-Nifedipine (Standard) is the analytical standard of m-Nifedipine. This product is intended for research and analytical applications. m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and agent of choice for cardiac insufficiencies .
|
-
- HY-B0356BS
-
|
BAY-09867-d8 (hydrochloride monohydrate)
|
Bacterial
Antibiotic
|
Infection
|
|
Ciprofloxacin-d8 (hydrochloride monohydrate) is the deuterium labeled Ciprofloxacin (hydrochloride monohydrate). Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
- HY-139788
-
|
ION-957943 free acid; BAY-3563450; IONIS-FXI-LRx
|
Others
|
Cardiovascular Disease
|
|
Fesomersen is an antisense oligonucleotide designed to inhibit the production of Factor XI.
|
-
- HY-B0284S
-
-
- HY-10331S
-
|
BAY 73-4506-d3
|
VEGFR
Autophagy
PDGFR
Raf
RET
|
Cancer
|
|
Regorafenib-d3 is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].
|
-
- HY-50903S
-
|
BAY 59-7939-d4
|
Factor Xa
|
Cardiovascular Disease
|
|
Rivaroxaban-d4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].
|
-
- HY-10201S1
-
-
- HY-B0745S
-
-
- HY-66011AS2
-
|
BAY 12-8039-d3
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Moxifloxacin-d3 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin hydrochloride is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2][3].
|
-
- HY-111372S
-
|
BAY 94-8862-d3
|
Mineralocorticoid Receptor
|
Others
|
|
Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
|
-
- HY-B0424S
-
|
AY-E-5009-d5
|
Calcium Channel
Autophagy
|
Cardiovascular Disease
|
|
Nitrendipine-d5 is the deuterium labeled Nitrendipine. Nitrendipine (BAY-E-5009), an analogue of Nifedipine (HY-B0284), is a dihydropyridine calcium channel blocker with vasodilator action. Nitrendipine has antihypertensive effect[1][2][3][4].
|
-
- HY-B0356AS
-
|
BAY-09867-dd8 (hydrochloride hydrate)
|
Bacterial
Antibiotic
|
Infection
|
|
Ciprofloxacin-d8 (hydrochloride hydrate) is the deuterium labeled Ciprofloxacin hydrochloride monohydrate. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
- HY-10201S
-
|
Donafenib; BAY 43-9006-d3
|
Raf
VEGFR
FLT3
Ferroptosis
Autophagy
Apoptosis
|
Cancer
|
|
Sorafenib-d3 (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .
|
-
- HY-66011AS
-
|
BAY 12-8039-d4 free base
|
Isotope-Labeled Compounds
Bacterial
Antibiotic
|
Infection
|
|
Moxifloxacin-d4 is the deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
|
-
- HY-N2022
-
|
|
Glucosidase
|
Inflammation/Immunology
Cancer
|
|
Castanospermine is a natural alkaloid that can be extracted from black beans or the Moreton Bay chestnut tree (Castanospermum australae). Castanospermine is an α/ β-glucosidase inhibitor. Castanospermine has anti-inflammatory, antiviral replication and anti-metastatic effects on prostate cancer. Castanospermine can be used as an immunosuppressant to prevent transplant rejection .
|
-
- HY-14779S
-
|
BAY 632521-13C,d6
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
Riociguat- 13C,d6 is the 13C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
|
-
- HY-131032
-
|
|
Adenosine Receptor
|
Others
|
|
KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC50=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC50s of 2390 nM and 2550 nM, respectively .
|
-
- HY-10201S2
-
|
|
Raf
VEGFR
FLT3
Autophagy
Apoptosis
Ferroptosis
|
Cancer
|
|
Sorafenib- 13C,d3 is the 13C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].
|
-
- HY-158119
-
|
|
PSMA
|
Cancer
|
|
Ac-PSMA-trillium is a PSMA targeting compound, consisting of a PSMA targeting molecule (PSMA binder), a Macropa chelating molecule, and a group that regulates pharmacokinetics (PK modifier). Ac-PSMA-trillium is a non-radioactive form of Actinium-225-PSMA-Trillium (BAY 3563254) with improved PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind Ac through the Macropa chelating molecule, or the radioactive isotope 225Actinium. Actinium-225-PSMA-Trillium is a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-158123
-
|
|
PSMA
|
Cancer
|
|
PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or it can be labeled with 225Ac (to obtain Actinium-225-PSMA-Trillium (BAY 3563254)), which has a radioactive killing effect; it can be used as a Macropa chelator for targeted radionuclide therapy (TRT) , has a strong inhibitory effect on metastatic castration-resistant prostate cancer (mCRPC) .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-B0497G
-
|
BAY2353 (GMP)
|
Fluorescent Dye
|
|
Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .
|
| Cat. No. |
Product Name |
Type |
-
- HY-144003
-
|
|
Drug Delivery
|
|
BAY-R 1005, an immunoenhancing agent, is a synthetic glycolipid analogue (GLA), which is supposed to modulate antibody synthesis .
|
-
- HY-W353258
-
|
BAY 12-8039 monohydrate
|
Biochemical Assay Reagents
|
|
Moxifloxacin (BAY 12-8039) hydrochloride monohydrate is an orally active bacterial inhibitor that is effective against Streptococcus pneumoniae. Moxifloxacin hydrochloride monohydrate can be used in tuberculosis research .
|
-
- HY-B0497G
-
|
BAY2353 (GMP)
|
Biochemical Assay Reagents
|
|
Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1160
-
|
|
GCGR
|
Metabolic Disease
|
|
Bay 55-9837 is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes .
|
-
- HY-P1160A
-
|
|
GCGR
|
Metabolic Disease
|
|
Bay 55-9837 TFA is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99718
-
|
BAY 1112623
|
ADC Antibody
|
Cancer
|
|
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 .
|
-
- HY-P99460
-
-
- HY-P99051
-
-
- HY-P99007
-
|
BAY 1179470
|
FGFR
|
Cancer
|
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
|
-
- HY-P99465
-
|
BAY 1093884
|
Thrombin
|
Cardiovascular Disease
|
|
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
|
-
- HY-P99794
-
|
BAY 1213790
|
Factor Xa
|
Cardiovascular Disease
|
|
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
|
-
- HY-P99802
-
|
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0356S1
-
|
|
|
Ciprofloxacin-d8 is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0356S
-
|
|
|
Ciprofloxacin-d8 (hydrochloride) is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-101566S
-
|
|
|
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .
|
-
-
- HY-B0497S1
-
|
|
|
Niclosamide- 13C6 is the 13C6 labeled Niclosamide. Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits STAT3 with IC50 of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.
|
-
-
- HY-16774S
-
|
|
|
Vericiguat-d3 (BAY1021189-d3) hydrochloride is a deuterated Vericiguat with tracer functionality. Vericiguat is an orally available stimulator of guanylate cyclase .
|
-
-
- HY-B0175S
-
|
|
|
Toltrazuril-d3 is deuterated labeled Toltrazuril. Toltrazuril (BAY-i 9142) is an antiprotozoal agent that acts upon Coccidia parasites.
|
-
-
- HY-B0284S1
-
|
|
|
Nifedipine-d4 is the deuterium labeled Nifedipine. Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
|
-
-
- HY-B1151S
-
|
|
|
Climbazole-d4 is the deuterium labeled Climbazole. Climbazole (BAY-e 6975) is a potent antifungal agent. Climbazole also is a potent inducer of rat hepatic cytochrome P450[2].
|
-
-
- HY-17402S
-
|
|
|
Nisoldipine-d6 is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552; Sular) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with an IC50 of 10 nM.
|
-
-
- HY-17402S3
-
|
|
|
Nisoldipine-d3 is deuterated labeled Nisoldipine (HY-17402). Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.
|
-
-
- HY-B0502S
-
|
|
|
Enrofloxacin-d5 is the deuterium labeled Enrofloxacin. Enrofloxacin (BAY Vp 2674) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.
|
-
-
- HY-B0502AS
-
|
|
|
Enrofloxacin-d5 (hydrochloride) is deuterium labeled Enrofloxacin (monohydrochloride). Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.
|
-
-
- HY-B0502AS1
-
|
|
|
Enrofloxacin-d5 (hydriodide) is the deuterium labeled Enrofloxacin (monohydrochloride). Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.
|
-
-
- HY-66011S
-
|
|
|
rac cis-Moxifloxacin-d4 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
|
-
-
- HY-66011AS3
-
|
|
|
Moxifloxacin-d3-1 hydrochloride (BAY 12-8039-d3-1) is a deuterium labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia .
|
-
-
- HY-B0497BS
-
|
|
|
Niclosamide- 13C6 (monohydrate) is the 13C labeled Niclosamide monohydrate[1]. Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used in parasitic infection research[2]. Niclosamide monohydrate is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[5]. Niclosamide monohydrate has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[3][4][6].
|
-
-
- HY-66011AS4
-
|
|
|
Moxifloxacin- 13C,d3 hydrochloride (BAY 12-8039- 13C,d3) is 13C and deuterated labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
|
-
-
- HY-10331S1
-
|
|
|
Regorafenib- 13C,d3 is the 13C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
|
-
-
- HY-120422S
-
|
|
|
N-Desmethyl Regorafenib-d3 is deuterium labeled BAY-751098.
|
-
-
- HY-17402S1
-
|
|
|
Nisoldipine-d4 (BAY-k 5552-d4) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM[1][2].
|
-
-
- HY-17402S2
-
|
|
|
Nisoldipine-d7 (BAY-k 5552-d7) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM[1][2].
|
-
-
- HY-B0481S1
-
|
|
|
Miglitol-d4 is deuterium labeled Miglitol.
|
-
-
- HY-B0265S
-
|
|
|
Nimodipine-d7 is the deuterium labeled Nimodipine. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].
|
-
-
- HY-B0356BS
-
|
|
|
Ciprofloxacin-d8 (hydrochloride monohydrate) is the deuterium labeled Ciprofloxacin (hydrochloride monohydrate). Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0284S
-
1 Publications Verification
|
|
Nifedipine-d6 is deuterium labeled nifedipine, and nifedipine is a potent calcium channel blocker.
|
-
-
- HY-10331S
-
|
|
|
Regorafenib-d3 is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].
|
-
-
- HY-50903S
-
1 Publications Verification
|
|
Rivaroxaban-d4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].
|
-
-
- HY-10201S1
-
|
|
|
Sorafenib-d4 is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
|
-
-
- HY-B0745S
-
|
|
|
Ramatroban-d4 is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.
|
-
-
- HY-66011AS2
-
|
|
|
Moxifloxacin-d3 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin hydrochloride is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2][3].
|
-
-
- HY-111372S
-
|
|
|
Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
|
-
-
- HY-B0424S
-
|
|
|
Nitrendipine-d5 is the deuterium labeled Nitrendipine. Nitrendipine (BAY-E-5009), an analogue of Nifedipine (HY-B0284), is a dihydropyridine calcium channel blocker with vasodilator action. Nitrendipine has antihypertensive effect[1][2][3][4].
|
-
-
- HY-B0356AS
-
|
|
|
Ciprofloxacin-d8 (hydrochloride hydrate) is the deuterium labeled Ciprofloxacin hydrochloride monohydrate. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-10201S
-
|
|
|
Sorafenib-d3 (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .
|
-
-
- HY-66011AS
-
|
|
|
Moxifloxacin-d4 is the deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
|
-
-
- HY-14779S
-
|
|
|
Riociguat- 13C,d6 is the 13C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
|
-
-
- HY-10201S2
-
1 Publications Verification
|
|
Sorafenib- 13C,d3 is the 13C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![(3β,25S)-Spirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-xylopyranosyl-(1→3)]-β-D-glucopyranoside](http://file.medchemexpress.com/product_pic/hy-n0345.gif)
